Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasted to Post Q2 2024 Earnings of ($0.64) Per Share

Sutro Biopharma, Inc. (NASDAQ:STRO) – Investment analysts at Wedbush issued their Q2 2024 EPS estimates for Sutro Biopharma in a research note issued to investors on Tuesday, November 14th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.64) for the quarter. Wedbush currently has a “Outperform” rating and a $12.00 target price on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.94) per share. Wedbush also issued estimates for Sutro Biopharma’s Q4 2024 earnings at ($0.83) EPS.

A number of other equities research analysts have also recently commented on STRO. Deutsche Bank Aktiengesellschaft started coverage on Sutro Biopharma in a research note on Thursday, November 9th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Sutro Biopharma in a research note on Tuesday. Oppenheimer initiated coverage on shares of Sutro Biopharma in a report on Thursday, October 5th. They issued an “outperform” rating and a $10.00 target price for the company. Truist Financial reissued a “buy” rating and set a $25.00 price target on shares of Sutro Biopharma in a research report on Wednesday, September 6th. Finally, JMP Securities restated a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a report on Monday, August 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Sutro Biopharma has an average rating of “Moderate Buy” and an average target price of $14.75.

Sutro Biopharma Stock Up 14.5 %

STRO stock opened at $2.37 on Wednesday. The business has a 50 day moving average of $3.36 and a 200 day moving average of $4.32. Sutro Biopharma has a twelve month low of $2.01 and a twelve month high of $8.72.

Insider Buying and Selling

In related news, insider Brunilda Shtylla sold 15,428 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $4.71, for a total transaction of $72,665.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is currently owned by insiders.

Institutional Trading of Sutro Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in STRO. Wells Fargo & Company MN grew its stake in shares of Sutro Biopharma by 331.7% in the fourth quarter. Wells Fargo & Company MN now owns 5,690 shares of the company’s stock valued at $46,000 after buying an additional 4,372 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Sutro Biopharma in the 1st quarter valued at about $56,000. Point72 Hong Kong Ltd acquired a new position in Sutro Biopharma in the 2nd quarter valued at about $46,000. Quantbot Technologies LP increased its stake in Sutro Biopharma by 117.1% during the first quarter. Quantbot Technologies LP now owns 8,900 shares of the company’s stock worth $73,000 after purchasing an additional 4,800 shares during the period. Finally, Advisor Group Holdings Inc. acquired a new stake in shares of Sutro Biopharma during the fourth quarter worth about $77,000. Hedge funds and other institutional investors own 89.40% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.